Article
DMD genomic deletions characterise a subset of progressive/higher-grade meningiomas with poor outcome
DMD Gendeletionen sind häufige genomische Ereignisse in progressiven und anaplastischen Meningeome
Search Medline for
Authors
Published: | May 8, 2019 |
---|
Outline
Text
Objective: While the female predominance in WHO grade I meningiomas is widely appreciated, it is also recognized that males have a tendency for more biologically aggressive tumors. The mechanisms by which sex can affect meningioma grade and growth are not fully understood yet.
Methods: We performed a comprehensive molecular characterization of 169 meningiomas from 53 patients with progressive/high-grade tumors, including matched primary and recurrent samples.
Results: Exome sequencing in an initial cohort (n=24) detected frequent alterations in genes residing on the X chromosome, with somatic intragenic deletions of the dystrophin-encoding and muscular dystrophy-associated DMD gene as the most common alteration (n=5, 20.8%), along with alterations of other known X-linked cancer-related genes KDM6A (n=2, 8.3%), DDX3X, RBM10 and STAG2 (n=1, 4.1% each). DMD inactivation (by genomic deletion or loss of protein expression) was ultimately detected in 17/53 progressive meningioma patients (32%). Patients with tumors harboring DMD inactivation had a shorter overall survival (OS) than their wild-type counterparts [5.1 years (95% CI 1.3–9.0) vs. median not reached (95% CI 2.9-not reached, p=0.006)]. Given the known poor prognostic association of TERT alterations in these tumors, we also assessed for these events, and found seven patients with TERT promoter mutations and three with TERT rearrangements in this cohort (n=10, 18.8%), including a recurrent novel RETREG1-TERT rearrangement that was present in two patients. In a multivariate model, DMD inactivation (p=0.033, HR=2.6, 95% CI 1.0–6.6) and TERT alterations (p=0.005, HR=3.8, 95% CI 1.5–9.9) were mutually independent in predicting unfavorable outcomes.
Conclusion: We discovered novel and frequently acquired genomic alterations on the sex chromosomes in addition to TERT rearrangements during progression in high-grade meningioma. DMD inactivation and TERT alterations identify a subset of progressive/high-grade meningiomas with worse outcomes. Thus, stratification for both genomic alterations can improve the design of progressive meningioma clinical trials and help improve patient management.